Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

Matthew C. Stubbs, Michelle Pusey, Xiaoming Wen, Katherine Drake, Nina Zolotarjova, Amanda Smith, Maryanne Covington, Guofeng Zhang, Ricardo Macarrón, Sunkyu Kim

Blood (2023) 142 (Supplement 1): 1789.

https://doi.org/10.1182/blood-2023-181055

Published: 2023

Journal Articles

Preclinical Evaluation of INCB160058 - a Novel and Potentially Disease-Modifying Therapy for JAK2V617F Mutant Myeloproliferative Neoplasms

Blood (2023) 142 (Supplement 1): 860.

https://doi.org/10.1182/blood-2023-179369

Published: 2023

Journal Articles

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression

Blood (2022) 139 (18): 2797–2815.

https://doi.org/10.1182/blood.2021013925

Published: 2022

Includes: Supplemental data

Journal Articles

HMGA1 Chromatin Regulators Drive Progression in Myeloproliferative Neoplasms through Epigenetic Rewiring to Induce Networks Involved in GATA2 and Proliferation

Liping Li, Jung-Hyun Kim, Wenyan Lu, Leslie Cope, Donna M Williams, Joseph Kim, Raajit Rampal, Richard Koche, Lingling Xian, Li Luo, Marija Vasiljevic, Daniel R Matson, Zhizhuang Joe Zhao, Ophelia Rogers, Matthew C. Stubbs, Karen Reddy, Jerry L. Spivak, Alison R. Moliterno, Linda Resar

Blood (2021) 138 (Supplement 1): 625.

https://doi.org/10.1182/blood-2021-144712

Published: 2021

Journal Articles

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Yaoyu Chen, Matthew C. Stubbs, PhD, Michelle Pusey, Xiaoming Wen, Robert J. Collins, Kanishk Kapilashrami, Mark Rupar, Pramod Thekkat, Luping Lin, PhD, Kevin Bowman, Yan-ou Yang, Sharon Diamond, Swamy Yeleswaram, PhD, Sunkyu Kim, Holly K. Koblish, PhD, Yingnan Chen, Susan Wee, PhD BS

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-136138

Published: 2020

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

Haley Ramsey, PhD MSc, Susu Zhang, Yue Zhao, PhD, Melissa Ann Fischer, PhD, Agnieszka Ewa Gorska, MSc, Maria Arrate, MSc, Londa Fuller, Dalton Greenwood, Matthew C. Stubbs, PhD, Phillip Liu, PhD, Jeffrey C Rathmell, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2018) 132 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2018-99-111393

Published: 2018

Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 717.

https://doi.org/10.1182/blood.V130.Suppl_1.717.717

Published: 2017

Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 1661.

https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661

Published: 2017

Journal Articles

Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All

Matthew C. Stubbs, PhD, Won-Il Kim, Ph.D., Tina Davis, Jun Qi, Ph.D., James Bradner, M.D., Andrew L. Kung, MD, PhD, Scott A. Armstrong, MD, PhD

Blood (2010) 116 (21): 2900.

https://doi.org/10.1182/blood.V116.21.2900.2900

Published: 2010

Journal Articles

Cell of Origin Influences Leukemia Stem Cell Phenotype.

Andrei V. Krivtsov, PhD, Amit U. Sinha, Matthew C. Stubbs, PhD, Andrew Kung, MD, PhD, Scott Armstrong, MD, PhD

Blood (2009) 114 (22): 3459.

https://doi.org/10.1182/blood.V114.22.3459.3459

Published: 2009

Journal Articles

HOXA9 is required for survival in human MLL -rearranged acute leukemias

Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis, Marry van den Heuvel-Eibrink, Christian M. Zwaan, Andrew L. Kung, Scott A. Armstrong

Blood (2009) 113 (11): 2375–2385.

https://doi.org/10.1182/blood-2007-09-113597

Published: 2009

Includes: Supplemental data

Journal Articles

The Myocyte Enhancer Factor 2C ( MEF2C ) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.

Jorg Faber, MD, PhD, Andrei V. Krivstov, PhD, Matthew C. Stubbs, PhD, Marry van den Heuvel-Eibrink, MD, PhD, Andrew L. Kung, MD, PhD, Christian M. Zwaan, MD, PhD, Scott A. Armstrong, MD, PhD

Blood (2007) 110 (11): 58.

https://doi.org/10.1182/blood.V110.11.58.58

Published: 2007

Journal Articles

HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy.

Matthew C. Stubbs, PhD, Joerg Faber, M.D., Ph.D., Andrew L. Kung, M.D., Ph.D., Scott Cameron, M.D., Ph.D., Scott A. Armstrong, M.D., Ph.D.

Blood (2007) 110 (11): 57.

https://doi.org/10.1182/blood.V110.11.57.57

Published: 2007

Journal Articles

MLL-AF9 Initiates Leukemia from a Single Committed Hematopoietic Progenitor.

Andrei V. Krivtsov, PhD, Matthew C. Stubbs, PhD, Renee Wright, Zhaohui Feng, Andrew L. Kung, MD,PhD, Scott A. Armstrong, MD,PhD

Blood (2006) 108 (11): 2534.

https://doi.org/10.1182/blood.V108.11.2534.2534

Published: 2006

Journal Articles

Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.

Matthew C. Stubbs, PhD, Teresa Kim, Andrei Krivtsov, Ph.D., Peter Atadja, Scott A. Armstrong, M.D., Ph.D., Andrew L. Kung, M.D., Ph.D.

Blood (2006) 108 (11): 1994.

https://doi.org/10.1182/blood.V108.11.1994.1994

Published: 2006

Journal Articles

HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.

Jorg Faber, MD, PhD, Andrei V. Krivtsov, PhD, Matthew C. Stubbs, PhD, Renee Wright, Marry van den Heuvel-Eibrink, MD PhD, Andrew L. Kung, MD PhD, Christian M. Zwaan, MD PhD, Scott A. Armstrong, MD PhD

Blood (2006) 108 (11): 734.

https://doi.org/10.1182/blood.V108.11.734.734

Published: 2006

Journal Articles

MLL-AF9 and FLT3 Cooperation during Myeloid Leukemogenesis: Development of a Model for Rapid Testing of New Therapeutics.

Matthew C. Stubbs, PhD, Andrei Krivtsov, PhD, Yong-mi Kim, MD, Renee D. Wright, Zhaohui Feng, Jyoti Agarwal, Andrew L. Kung, MD, PhD, Scott A. Armstrong, MD, PhD

Blood (2005) 106 (11): 1605.

https://doi.org/10.1182/blood.V106.11.1605.1605

Published: 2005

Journal Articles

MLL -Fusion Proteins Induce a Stem Cell Program in Committed Progenitors To Generate Leukemia Stem Cells.

Andrei V. Krivstov, PhD, David Twomey, Zhaohui Feng, Matthew C. Stubbs, PhD, Todd R. Golub, MD, Scott A. Armstrong, MD, PhD.

Blood (2005) 106 (11): 465.

https://doi.org/10.1182/blood.V106.11.465.465

Published: 2005

NARROW

ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

Preclinical Evaluation of INCB160058 - a Novel and Potentially Disease-Modifying Therapy for JAK2V617F Mutant Myeloproliferative Neoplasms

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression

HMGA1 Chromatin Regulators Drive Progression in Myeloproliferative Neoplasms through Epigenetic Rewiring to Induce Networks Involved in GATA2 and Proliferation

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All

Cell of Origin Influences Leukemia Stem Cell Phenotype.

HOXA9 is required for survival in human MLL -rearranged acute leukemias

The Myocyte Enhancer Factor 2C ( MEF2C ) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.

HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy.

MLL-AF9 Initiates Leukemia from a Single Committed Hematopoietic Progenitor.

Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.

HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.

MLL-AF9 and FLT3 Cooperation during Myeloid Leukemogenesis: Development of a Model for Rapid Testing of New Therapeutics.

MLL -Fusion Proteins Induce a Stem Cell Program in Committed Progenitors To Generate Leukemia Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only